The 2023 Fall Clinical Dermatology conference featured research on treatments for alopecia areata, acne, psoriasis, atopic dermatitis, and vitiligo.
The Fall Clinical Dermatology conference presented research on safe and effective therapy treatments for alopecia areata, acne, psoriasis, atopic dermatitis, and vitiligo, and here we present some of the highlights.
Our full coverage from the Fall Clinical Dermatology 2023 conference can be found here.
5. Baricitinib Effective in Treating Alopecia Areata
A poster displayed at the conference presented research showing baricitinib was effective in treating adult patients with alopecia areata (AA). AA, a hair loss disorder that can affect any hair-bearing site, has limited data on Janus kinase (JAK) inhibitors as a form of treatment. The posters presented an assessment of adults with AA who had 50% or more hair loss and determined baricitinib maintained efficacy in 90% of patients, and the medication appeared safe.
4. Panel Discusses Treating Acne, Psoriasis in Dermatology Patients
A panel of experts gathered at the Fall Clinical Dermatology conference to discuss treatments for acne and psoriasis beyond the usual topical therapies. The acne panel focused their discussion on combination therapies, specifying the importance of retinoids, topical antibiotics, and benzoyl peroxide. Aside from combination therapy, experts stressed simplifying the treatment regimen for the consumer benefit, without altering the effectiveness of the medication. The panel switched topics to psoriasis, suggesting a new treatment rather than topical steroids. Two creams, tapinarof and rolumilast, were found to be safer, cheaper, and equally effective as topical steroids. New ways to treat patients safely and effectively were highlighted throughout the panel discussion.
3. Dupilumab Found Effective, Safe as Long-Term Treatment in Adults with Atopic Dermatitis
Two posters at the Fall Clinical Dermatology conference reported separate studies from an open-label extension trial taking place over 5 years among patients with atopic dermatitis (AD). In one poster, patients with AD had long-term safety and efficacy when treated with dupilumab throughout 5 years. There were major improvements in the signs and symptoms of AD as well. The second poster displayed similar results to the first, with the researchers declaring both studies consistent with an acceptable safety profile.
2. New and Upcoming Treatment for Vitiligo, Atopic Dermatitis
Treatment strategies for vitiligo and AD were covered in a panel discussion at the conference. Therapy for vitiligo includes topical, systemic, and procedural treatments; topical therapy consists of oral antioxidants, oral/topical medications, and phototherapy whereas JAK inhibitors are a form of systemic therapy. Procedural therapy includes melanocyte and keratinocyte transplants in the office using lasers and durablades. The combination of dupilumab and JAK inhibitors was proposed as therapy for patients with AD because both reduce the itch-scratch cycle by reversing neurological hyperreactive states. The mixture of the 2 therapies resulted in a safe and effective treatment for patients with AD.
1. Ruxolitinib, Povorcitinib Effective in Treating Vitiligo, According to Posters
An evaluation of ruxolitinib and povorcitinib in treating nonsegmental vitiligo was presented among 2 posters at the conference. The first poster displayed effective response to ruxolitinib among adults and adolescents with nonsegmental vitiligo despite their differences in demographics and characteristics. The second poster demonstrated exceptional improvements in patients treated with oral povorcitinib, resulting in facial and total body repigmentation. Overall, both ruxolitinib and povorcitinib were cited as effective treatment methods for nonsegmental vitiligo.
Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT
April 22nd 2024A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.
Read More
Secukinumab Proves Successful in Treating Severe HS, Safety Persists at Week 52
April 11th 2024In a recent study, secukinumab therapy demonstrated adequate safety and efficacy profiles, offering potential benefits for patients with severe hidradenitis suppurativa (HS) who found adalimumab intolerable.
Read More
Delays in HS Diagnosis, Treatment Shed Light on Provider Education Gaps
April 5th 2024Patients with hidradenitis suppurativa (HS) in Canada often wait long periods of time to receive an HS diagnosis and receive evidence-based therapy, highlighting the need for increased interdisciplinary education on HS management.
Read More
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
AI Dermatology Mobile Apps Have Critical Efficacy, Safety Gaps, Review Says
March 17th 2024This scoping review discovered potential risks and critical gaps in the efficacy, safety, and transparency of current artificial intelligence (AI) dermatology mobile apps, emphasizing the need for regulatory intervention.
Read More